Antiresorptive & Osteoporosis Medications

01 — Risk Tiers

Dose and route drive the risk

MRONJ risk scales with cumulative antiresorptive exposure. Implant-associated MRONJ in osteoporosis patients on denosumab has been reported around 0.5% — low, but not zero. Always document informed consent for both MRONJ and elevated implant-failure risk.

Low risk

Osteoporosis dose, < 4 yrs

Oral bisphosphonate, short duration
No concurrent steroids
MRONJ risk very low (~0.5% range)
Implants generally appropriate

Elevated risk

Osteoporosis dose, > 4 yrs / steroids

Long-duration oral or SC therapy
Concurrent corticosteroids / RA
Drug-holiday consideration zone
Proceed with caution + consent

High risk

Oncologic / high-dose IV

IV zoledronate / high-dose denosumab for malignancy
± antiangiogenics, chemotherapy
Implants generally contraindicated
Coordinate with oncology

02 — Drug Reference

Know the drug class — it changes the plan

A "drug holiday" means different things by class. Bisphosphonates bind bone for years (holiday value debated); denosumab is reversible, so timing within its dosing cycle is the real lever.

Drug	Class	MRONJ relevance	Key point
Alendronate / risedronate	Oral bisphosphonate	Low at osteoporosis dose	Persists in bone; holiday effect uncertain
Zoledronate (IV)	IV bisphosphonate	Low (osteoporosis) / high (oncologic)	Dose & frequency define risk
Denosumab (Prolia)	Antiresorptive (RANKL)	Low at osteoporosis dose	Reversible — plan around 6-mo dosing
Denosumab (Xgeva, oncologic)	High-dose antiresorptive	High	Avoid elective implants
Romosozumab	Anabolic / antiresorptive	Rare MRONJ reports	Lower risk than BP/denosumab
Teriparatide / abaloparatide	Anabolic (PTH analog)	Not an MRONJ risk	May aid healing in some cases

03 — Decision Pathway

Interactive risk selector

Identify the dose/indication first; it dominates the decision. Then layer duration and steroid co-therapy.

Tap the scenario that matches the patient's medication profile.

Step 1 — What is the indication and dose?

LOW

Osteoporosis dose, < 4 yrs, no steroids

Oral BP or Prolia, short course.

ELEVATED

Osteoporosis dose > 4 yrs or on steroids

Longer exposure / added risk factors.

ONCOLOGIC

High-dose IV / oncologic antiresorptive

Malignancy indication ± antiangiogenics.

▾

04 — Guideline Note

Where the consensus stands (and disagrees)

Guidance is evidence-thin and not fully aligned — flag this in your own consent discussion rather than presenting one position as settled.

Topic	Current position
Drug holiday (oral BP)	AAOMS (2022): consider ≥2-month discontinuation pre-surgery if >4 yrs therapy or steroids and fracture risk permits. Evidence weak; no RCTs.
Stopping therapy for implants	2025 ONJ Taskforce (Endocrine Practice): antiresorptive therapy need not be stopped before implant placement (weak rec, very-low-quality evidence).
CTX / biomarker testing	Not validated for clinical decision-making — do not rely on it.
Denosumab timing	Reversible effect; coordinate elective surgery with the 6-month dosing trough where feasible.

Reference

Sources & clinical disclaimer

For licensed clinicians — educational use only. This algorithm summarizes published consensus that is evolving and not fully harmonized; it is not a substitute for individual clinical judgment, examination, prescriber consultation, or the standard of care in your jurisdiction. Always coordinate antiresorptive management with the patient's physician. Do not alter a patient's medication without prescriber agreement.

Ruggiero SL, et al. AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaws — 2022 Update. J Oral Maxillofac Surg. 2022;80(5):920–943.
ONJ Taskforce. Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes — Consensus Statement. Endocr Pract. 2025.
Pereira Santos, et al. MRONJ risk related to dental implants in osteoporosis treated with denosumab: a systematic review. Oral Dis. 2025.

Last reviewed: June 2026 · Next review due: June 2027 · Version 1.0